No Data
No Data
Insiders' US$5.17m Investments In Red Following Terns Pharmaceuticals' US$52m Dip In Market Value
TD Cowen Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating
All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy
Oppenheimer Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating, Maintains Target Price $20
Terns Pharmaceuticals Reports 2024 Progress and Outlook
Terns Pharmaceuticals: Promising Investment With Strong Financials and Strategic Developments